AI Article Synopsis
- 5-Azacitidine (5-AZA) is commonly used to treat higher-risk myelodysplastic syndromes but shows significant variability in response and survival rates among patients.
- The review emphasizes the importance of identifying clinical, morphological, cytogenetic, and molecular factors that influence treatment outcomes.
- It also explores predictive biomarkers linked to the effectiveness of 5-AZA, suggesting that these could enhance prognostic classifications for better patient management in the future.
Article Abstract
5-Azacitidine (5-AZA) is widely used for the treatment of higher-risk myelodysplastic syndromes. However, response and survival rates vary considerably, while indicated treatment duration remains undefined. For these reasons, factors determining response and survival are of major importance. Clinical, morphological, flow cytometry, cytogenetic and molecular factors are discussed in this review. Biomarkers predictive of response and prognosis, as well as their link to the mode of action of 5-AZA are also addressed, shifting the focus from clinical practice to investigational research. Their use could further improve prognostic classification of 5-AZA treated higher-risk myelodysplastic syndromes in the near future.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2217/epi-2021-0124 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!